Department of Neurosurgery, The Second Affiliated Hospital, Anhui Medical University, Hefei, China; Department of Neurosurgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Neurosurgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Department of Neurosurgery, Second Hospital of Shanxi Medical University Taiyuan, China.
Clinics (Sao Paulo). 2023 May 16;78:100212. doi: 10.1016/j.clinsp.2023.100212. eCollection 2023.
To explore the expression levels and clinical value of FKBP10 in lung adenocarcinoma brain metastases.
A retrospective single-institution cohort study.
The perioperative records of 71 patients with lung adenocarcinoma brain metastases who underwent surgical resection at the authors' institution between November 2012 and June 2019 were retrospectively analyzed.
The authors evaluated FKBP10 expression levels using immunohistochemistry in tissue arrays of these patients. Kaplan-Meier survival curves were constructed, and a Cox proportional hazards regression model was used to identify independent prognostic biomarkers. A public database was used to detect FKBP10 expression and its clinical value in primary lung adenocarcinoma.
The authors found that the FKBP10 protein was selectively expressed in lung adenocarcinoma brain metastases. Survival analysis showed that FKBP10 expression (p = 0.02, HR = 2.472, 95% CI [1.156, 5.289]), target therapy (p < 0.01, HR = 0.186, 95% CI [0.073, 0.477]), and radiotherapy (p = 0.006, HR = 0.330, 95% CI [0.149, 0.731]) were independent prognostic factors for survival in lung adenocarcinoma patients with brain metastases. The authors also detected FKBP10 expression in primary lung adenocarcinoma using a public database, found that FKBP10 is also selectively expressed in primary lung adenocarcinoma, and affects the overall survival and disease-free survival of patients.
The number of enrolled patients was relatively small and patients' treatment options varied.
A combination of surgical resection, adjuvant radiotherapy, and precise target therapy may benefit the survival of selected patients with lung adenocarcinoma brain metastases. FKBP10 is a novel biomarker for lung adenocarcinoma brain metastases, which is closely associated with survival time and may serve as a potential therapeutic target.
探讨 FKBP10 在肺腺癌脑转移中的表达水平及其临床价值。
回顾性单中心队列研究。
回顾性分析 2012 年 11 月至 2019 年 6 月作者所在机构行手术切除的 71 例肺腺癌脑转移患者的围手术期记录。
采用免疫组织化学方法对这些患者的组织芯片进行 FKBP10 表达水平评估。绘制 Kaplan-Meier 生存曲线，并采用 Cox 比例风险回归模型确定独立的预后生物标志物。使用公共数据库检测原发性肺腺癌中 FKBP10 的表达及其临床价值。
作者发现 FKBP10 蛋白在肺腺癌脑转移中选择性表达。生存分析表明，FKBP10 表达（p=0.02，HR=2.472，95%CI[1.156，5.289]）、靶向治疗（p<0.01，HR=0.186，95%CI[0.073，0.477]）和放疗（p=0.006，HR=0.330，95%CI[0.149，0.731]）是肺腺癌脑转移患者生存的独立预后因素。作者还使用公共数据库检测了原发性肺腺癌中的 FKBP10 表达，发现 FKBP10 也在原发性肺腺癌中选择性表达，并影响患者的总生存和无病生存。
入组患者数量相对较少，患者的治疗选择存在差异。
手术切除联合辅助放疗和精准靶向治疗可能使部分肺腺癌脑转移患者受益。FKBP10 是肺腺癌脑转移的一个新的生物标志物，与生存时间密切相关，可能成为潜在的治疗靶点。
